Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Friday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to issue its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $0.70 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Atara Biotherapeutics Stock Down 0.6%

NASDAQ:ATRA opened at $5.39 on Thursday. The firm’s fifty day simple moving average is $7.73 and its 200 day simple moving average is $11.77. The stock has a market cap of $38.86 million, a P/E ratio of 2.47 and a beta of -0.44. Atara Biotherapeutics has a twelve month low of $3.92 and a twelve month high of $19.15.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Atara Biotherapeutics in a research report on Monday, December 29th. New Street Research set a $6.00 target price on Atara Biotherapeutics in a report on Tuesday, January 13th. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $6.00 target price (down from $25.00) on shares of Atara Biotherapeutics in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Atara Biotherapeutics presently has a consensus rating of “Reduce” and an average target price of $6.00.

Insider Activity

In other news, major shareholder Innovation Ltd Panacea sold 80,554 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $6.07, for a total value of $488,962.78. Following the sale, the insider directly owned 1,324,446 shares of the company’s stock, valued at $8,039,387.22. The trade was a 5.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in shares of Atara Biotherapeutics in the second quarter worth $31,000. Dimensional Fund Advisors LP bought a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at about $181,000. Walleye Capital LLC purchased a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at about $220,000. Marshall Wace LLP bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $327,000. Finally, Quadrature Capital Ltd lifted its stake in shares of Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 3,779 shares during the period. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.